MOTS-c

Not FDA approvedMitochondrial ResearchWeight & metabolicLongevity & cellular
6.0

Worth trying, BioHarmony verdict

BioHarmony score 6.0 out of 10

MOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway. Human evidence remains observational: Zhou 2024 pooled seven biomarker studies, but no published human RCT has tested exogenous MOTS-c for clinical outcomes.

Read full report

What is MOTS-c?

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded inside the mitochondrial 12S rRNA region. The core finding from Lee 2015 is that MOTS-c can regulate insulin sensitivity and metabolic homeostasis by inhibiting the folate and purine biosynthesis pathway, raising AICAR, and activating AMPK, the same energy-sensing pathway stimulated by exercise and caloric stress.

From the BioHarmony report, reviewed Sep 8, 2026.

Saved on this device only.

How it is thought to work

Inhibits ATIC in the folate and purine biosynthesis pathway, increases AICAR, activates AMPK, and can translocate to the nucleus during metabolic stress per Kim 2018.

Safety watch-outs

  • Injection-site infection
  • Hypoglycemia symptoms
  • Severe fatigue or muscle weakness

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

No approved-label or study protocol is recorded for MOTS-c yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (6)

Attributed viewpoints, separate from primary research.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalNot FDA approved
CompoundingWithdrawn from Category 2 nomination; eligibility is not established

FDA identifies immunogenicity and impurity concerns for compounded MOTS-c and says it has not identified human exposure data or enough information to determine harm.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.